UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2020
Commission File Number: 001-39173
I-MAB
Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District
Shanghai, 201210
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| I-MAB | ||
| By : | /s/ Jielun Zhu | |
| Name : | Jielun Zhu | |
| Title : | Director and Chief Financial Officer | |
Date: April 8, 2020
Exhibit Index
Exhibit 99.1—Press Release
Exhibit 99.1 April 2020 I-MAB PresentationExhibit 99.1 April 2020 I-MAB Presentation
Disclaimer This presentation has been prepared by I-Mab (the “Company”) solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed. This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the “SEC”) or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,” “intends,” “anticipates,” “believes,” “confident,” or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company’s operations and other factors, many of which are beyond the Company’s control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances. THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized. By viewing, accessing, or participating in this presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. 2 I-MAB INVESTOR PRESENTATIONDisclaimer This presentation has been prepared by I-Mab (the “Company”) solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed. This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the “SEC”) or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,” “intends,” “anticipates,” “believes,” “confident,” or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company’s operations and other factors, many of which are beyond the Company’s control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances. THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized. By viewing, accessing, or participating in this presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. 2 I-MAB INVESTOR PRESENTATION
Key Investment Highlights Novel or Highly Clinical Stage Commercial Stage $500m+ Raised Differentiated Company in 2 Years Nasdaq listed Immuno-oncology Expected product From private 8 late-stage and and autoimmune launch 2021 rounds 2016-2019 early-stage assets disease onwards and IPO 2020 Moving towards a fully integrated Founded as a discovery global biopharma in 3-5 years focused start-up in 2016 3 I-MAB INVESTOR PRESENTATIONKey Investment Highlights Novel or Highly Clinical Stage Commercial Stage $500m+ Raised Differentiated Company in 2 Years Nasdaq listed Immuno-oncology Expected product From private 8 late-stage and and autoimmune launch 2021 rounds 2016-2019 early-stage assets disease onwards and IPO 2020 Moving towards a fully integrated Founded as a discovery global biopharma in 3-5 years focused start-up in 2016 3 I-MAB INVESTOR PRESENTATION
I-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0 A Commercial stage company with full scale R&D and manufacture capability Serial BLA filings expected from 2021 onwards Fully Integrated Global A clinical stage company with Biopharma global operations 2024 8-10 clinical programs in US and China I-Mab 2.0 ▪ Delivering clinical and corporate catalysts 2020 ▪ Building commercial capability/partnership ▪ Building manufacture capability Nasdaq Listing ▪ Expanding global and regional partnerships I-Mab 1.0 ▪ Global portfolio of 12 assets 2016 ▪ China portfolio of 5 licensed clinical assets ▪ Raised US$ 500m from private rounds and IPO ▪ R&D capability and global footprint Focusing on Novel and Highly Differentiated Biologics COMPANY OVERVIEW 4 I-MAB INVESTOR PRESENTATIONI-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0 A Commercial stage company with full scale R&D and manufacture capability Serial BLA filings expected from 2021 onwards Fully Integrated Global A clinical stage company with Biopharma global operations 2024 8-10 clinical programs in US and China I-Mab 2.0 ▪ Delivering clinical and corporate catalysts 2020 ▪ Building commercial capability/partnership ▪ Building manufacture capability Nasdaq Listing ▪ Expanding global and regional partnerships I-Mab 1.0 ▪ Global portfolio of 12 assets 2016 ▪ China portfolio of 5 licensed clinical assets ▪ Raised US$ 500m from private rounds and IPO ▪ R&D capability and global footprint Focusing on Novel and Highly Differentiated Biologics COMPANY OVERVIEW 4 I-MAB INVESTOR PRESENTATION
Innovative and Risk-Balanced Pipeline: Two Portfolios China China Strategy – Fast-to-Market 5 clinical assets BLA 2021 onwards Global In - li cen si ng China Discovery Pre-Clinical IND Enabling Phase 1 / Phase 2 Phase 3 BLA Marketing China US Global Partnership Global Global Strategy – Fast-to-PoC Internal R&D Clinical Validation 12 clinical & pre-clinical assets Rockville, MD Shanghai Beijing COMPANY OVERVIEW 5 I-MAB INVESTOR PRESENTATIONInnovative and Risk-Balanced Pipeline: Two Portfolios China China Strategy – Fast-to-Market 5 clinical assets BLA 2021 onwards Global In - li cen si ng China Discovery Pre-Clinical IND Enabling Phase 1 / Phase 2 Phase 3 BLA Marketing China US Global Partnership Global Global Strategy – Fast-to-PoC Internal R&D Clinical Validation 12 clinical & pre-clinical assets Rockville, MD Shanghai Beijing COMPANY OVERVIEW 5 I-MAB INVESTOR PRESENTATION
Innovative Pipeline of Novel and Highly Differentiated Potential Expected Indication/ Commercial Drug Candidate (Licensor) Preclinical Phase 1 Phase 2 Phase 3 NDA / BLA Therapeutic Area Rights Filing (1) TJ202 (MorphoSys) Multiple myeloma/ Greater China BLA 2021 Autoimmune disease Differentiated CD38 antibody (2) Pediatric growth Eftansomatropin TJ101 (Genexine) Greater China BLA 2023 hormone deficiency Long-acting growth hormone Olamkicept TJ301 (Ferring) Ulcerative colitis/ Greater China 2021-2024 Soluble gp130 IL-6 inhibitor Autoimmune disease S. Korea (3) Head and neck Enoblituzumab (MacroGenics) Greater China cancer/ Oncology B7-H3 antibody Efineptakin TJ107 (Genexine) Oncology-related Greater China Novel long-acting IL-7 lymphopenia Autoimmune TJM2 disease/Cytokine Global GM-CSF antibody release syndrome TJC4 Multiple cancer Global Differentiated CD47 antibody indications Multiple cancer TJD5 Global indications Differentiated CD73 antibody TJ210 (MorphoSys) Oncology/ Greater China 2024- Differentiated C5aR antibody Autoimmune disease Global shared TJX7 Autoimmune disease Global Novel CXCL13 antibody (4) Bi-specific antibody panel Multiple cancer Global including five PD-L1-based bi- indications Some shared specifics, TJ-C4GM and TJ- CLDN4B Notes 1. TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus (“SLE”) in the first half of 2020 2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020 3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA’s regulatory approval) by the end of 2020 4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B (PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM- CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB) COMPANY OVERVIEW 6 I-MAB INVESTOR PRESENTATION Global Portfolio China PortfolioInnovative Pipeline of Novel and Highly Differentiated Potential Expected Indication/ Commercial Drug Candidate (Licensor) Preclinical Phase 1 Phase 2 Phase 3 NDA / BLA Therapeutic Area Rights Filing (1) TJ202 (MorphoSys) Multiple myeloma/ Greater China BLA 2021 Autoimmune disease Differentiated CD38 antibody (2) Pediatric growth Eftansomatropin TJ101 (Genexine) Greater China BLA 2023 hormone deficiency Long-acting growth hormone Olamkicept TJ301 (Ferring) Ulcerative colitis/ Greater China 2021-2024 Soluble gp130 IL-6 inhibitor Autoimmune disease S. Korea (3) Head and neck Enoblituzumab (MacroGenics) Greater China cancer/ Oncology B7-H3 antibody Efineptakin TJ107 (Genexine) Oncology-related Greater China Novel long-acting IL-7 lymphopenia Autoimmune TJM2 disease/Cytokine Global GM-CSF antibody release syndrome TJC4 Multiple cancer Global Differentiated CD47 antibody indications Multiple cancer TJD5 Global indications Differentiated CD73 antibody TJ210 (MorphoSys) Oncology/ Greater China 2024- Differentiated C5aR antibody Autoimmune disease Global shared TJX7 Autoimmune disease Global Novel CXCL13 antibody (4) Bi-specific antibody panel Multiple cancer Global including five PD-L1-based bi- indications Some shared specifics, TJ-C4GM and TJ- CLDN4B Notes 1. TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus (“SLE”) in the first half of 2020 2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020 3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA’s regulatory approval) by the end of 2020 4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B (PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM- CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB) COMPANY OVERVIEW 6 I-MAB INVESTOR PRESENTATION Global Portfolio China Portfolio
The Emerging Value Drivers: Critical Product Differentiation Clinical Assets Key Differentiation Clinical Development Plan Short infusion time (0.5 – 2 hrs) and lower IRR (7%) ▪ Two on-going registrational trials in MM to target TJ202 BLA in 2021 Differentiated CD38 mAb ▪ Ph 1b trial in SLE in 2020 nd Combination with Lenalidomide as 2 line therapy Convenient weekly dosing vs. daily injections TJ101 ▪ Planned IND for Ph 3 in PGHD in mid 2020 Differentiated ▪ BLA expected in 2023 long-acting hGH Better safety profile (HyFc) vs. pegylated hGH Strong anti-tumor activity US trial on-going in solid tumor/lymphoma: Minimal binding to RBC due to a unique epitope ▪ Safety advantage (dose-escalation, 1-30 mg/kg) TJC4 ▪ Combination with PD-1/CD20 Differentiated CD47 mAb No severe anemia (GLP tox up to 100 mg/kg) China trial starting: AML/MDS Intra-dimerization mechanism: no “hook effect” ▪ US trial on-going: Phase 1 combo with PD-L1 TJD5 ▪ China trial starting: Phase 1 combo with PD-1 Differentiated CD73 mAb MoA with broader tumor indications COMPANY OVERVIEW 7 I-MAB INVESTOR PRESENTATIONThe Emerging Value Drivers: Critical Product Differentiation Clinical Assets Key Differentiation Clinical Development Plan Short infusion time (0.5 – 2 hrs) and lower IRR (7%) ▪ Two on-going registrational trials in MM to target TJ202 BLA in 2021 Differentiated CD38 mAb ▪ Ph 1b trial in SLE in 2020 nd Combination with Lenalidomide as 2 line therapy Convenient weekly dosing vs. daily injections TJ101 ▪ Planned IND for Ph 3 in PGHD in mid 2020 Differentiated ▪ BLA expected in 2023 long-acting hGH Better safety profile (HyFc) vs. pegylated hGH Strong anti-tumor activity US trial on-going in solid tumor/lymphoma: Minimal binding to RBC due to a unique epitope ▪ Safety advantage (dose-escalation, 1-30 mg/kg) TJC4 ▪ Combination with PD-1/CD20 Differentiated CD47 mAb No severe anemia (GLP tox up to 100 mg/kg) China trial starting: AML/MDS Intra-dimerization mechanism: no “hook effect” ▪ US trial on-going: Phase 1 combo with PD-L1 TJD5 ▪ China trial starting: Phase 1 combo with PD-1 Differentiated CD73 mAb MoA with broader tumor indications COMPANY OVERVIEW 7 I-MAB INVESTOR PRESENTATION
TJC4: Minimal Binding to Red Blood Cells by Design RBC Agglutination 1 2 T J C 4 5 F 9 2 A 1 9 IgG 6 5F9 3 2A1 0 TJC4 m g / m l RBC Binding 1 0 0 8 0 IgG 6 0 TJC4 4 0 5F9 2 0 0 2A1 I g G T J C 4 5 F 9 2 A 1 COMPANY OVERVIEW 8 I-MAB INVESTOR PRESENTATION 0 . 0 0 3 0 . 0 1 0 . 0 3 0 . 1 0 . 3 1 3 1 0 3 0 1 0 0 % o f R B C b i n d i n g A g g l u t i n a t i o n i n d e xTJC4: Minimal Binding to Red Blood Cells by Design RBC Agglutination 1 2 T J C 4 5 F 9 2 A 1 9 IgG 6 5F9 3 2A1 0 TJC4 m g / m l RBC Binding 1 0 0 8 0 IgG 6 0 TJC4 4 0 5F9 2 0 0 2A1 I g G T J C 4 5 F 9 2 A 1 COMPANY OVERVIEW 8 I-MAB INVESTOR PRESENTATION 0 . 0 0 3 0 . 0 1 0 . 0 3 0 . 1 0 . 3 1 3 1 0 3 0 1 0 0 % o f R B C b i n d i n g A g g l u t i n a t i o n i n d e x
TJC4: Safety Advantage Demonstrated in Cyno Monkeys Pilot-single dose 4-wk GLP-Tox R B C s H e m o g l o b i n P B S 6 P B S 1 6 R B C s 5 F 9 5 F 9 1 4 5 T J C 4 T J C 4 7 1 2 V e h i c l e 4 1 0 6 T J C 4 ( 1 0 m g / k g ) 3 8 T J C 4 ( 3 0 m g / k g ) 5 6 2 T J C 4 ( 1 0 0 m g / k g ) 4 4 1 Male 2 3 0 0 - 8 - 4 0 4 8 1 2 1 6 2 0 2 4 - 8 - 4 0 4 8 1 2 1 6 2 0 2 4 2 D a y D a y 1 0 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 D a y s Pilot-repeat dose R B C s 7 V e h i c l e T J C 4 ( 1 0 m g / k g ) 6 T J C 4 ( 3 0 m g / k g ) 5 R B C s H e m o g l o b i n T J C 4 ( 1 0 0 m g / k g ) 4 7 P B S 1 6 P B S Female T J C 4 T J C 4 1 4 6 3 1 2 5 2 1 0 4 8 1 3 6 0 2 4 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 1 2 D a y s 0 0 0 7 1 4 2 1 2 8 3 5 0 7 1 4 2 1 2 8 3 5 D a y s D a y s COMPANY OVERVIEW 9 I-MAB INVESTOR PRESENTATION 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L ) H e m o g l o b i n ( g / d L ) H e m o g l o b i n ( g / d L ) 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L )TJC4: Safety Advantage Demonstrated in Cyno Monkeys Pilot-single dose 4-wk GLP-Tox R B C s H e m o g l o b i n P B S 6 P B S 1 6 R B C s 5 F 9 5 F 9 1 4 5 T J C 4 T J C 4 7 1 2 V e h i c l e 4 1 0 6 T J C 4 ( 1 0 m g / k g ) 3 8 T J C 4 ( 3 0 m g / k g ) 5 6 2 T J C 4 ( 1 0 0 m g / k g ) 4 4 1 Male 2 3 0 0 - 8 - 4 0 4 8 1 2 1 6 2 0 2 4 - 8 - 4 0 4 8 1 2 1 6 2 0 2 4 2 D a y D a y 1 0 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 D a y s Pilot-repeat dose R B C s 7 V e h i c l e T J C 4 ( 1 0 m g / k g ) 6 T J C 4 ( 3 0 m g / k g ) 5 R B C s H e m o g l o b i n T J C 4 ( 1 0 0 m g / k g ) 4 7 P B S 1 6 P B S Female T J C 4 T J C 4 1 4 6 3 1 2 5 2 1 0 4 8 1 3 6 0 2 4 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 1 2 D a y s 0 0 0 7 1 4 2 1 2 8 3 5 0 7 1 4 2 1 2 8 3 5 D a y s D a y s COMPANY OVERVIEW 9 I-MAB INVESTOR PRESENTATION 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L ) H e m o g l o b i n ( g / d L ) H e m o g l o b i n ( g / d L ) 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L )
TJC4: Comparable Anti-Tumor Activity in Animal Models 9 1 0 I g G ( 1 0 m g / k g ) T J C 4 ( 1 0 m g / k g ) 5 F 9 ( 1 0 m g / k g ) 8 1 0 2 A 1 ( 1 0 m g / k g ) 7 1 0 5 days i.p. injection q2d 6 CD47 Abs treatment Inject 1x10 Luci- 6 1 0 started 5 days post Raji cells via tail engraftment vein in NSG mice 5 1 0 0 2 4 6 8 1 0 D a y s p o s t t r e a t m e n t IgG 5F9 2A1 TJC4 Treatment of TJC4 eradicated the engrafted tumor cells, comparable to 5F9 and 2A1 reference mAbs. COMPANY OVERVIEW 10 I-MAB INVESTOR PRESENTATION L u m i n e s c e n c e i n t e n s i t yTJC4: Comparable Anti-Tumor Activity in Animal Models 9 1 0 I g G ( 1 0 m g / k g ) T J C 4 ( 1 0 m g / k g ) 5 F 9 ( 1 0 m g / k g ) 8 1 0 2 A 1 ( 1 0 m g / k g ) 7 1 0 5 days i.p. injection q2d 6 CD47 Abs treatment Inject 1x10 Luci- 6 1 0 started 5 days post Raji cells via tail engraftment vein in NSG mice 5 1 0 0 2 4 6 8 1 0 D a y s p o s t t r e a t m e n t IgG 5F9 2A1 TJC4 Treatment of TJC4 eradicated the engrafted tumor cells, comparable to 5F9 and 2A1 reference mAbs. COMPANY OVERVIEW 10 I-MAB INVESTOR PRESENTATION L u m i n e s c e n c e i n t e n s i t y
TJC4: Parallel Clinical Development in US and China US development goals: ▪ Evaluation of the safety differentiation in solid tumor/lymphoma to complete by Q3 ▪ Combination therapy with PD-1 inhibitor pembrolizumab (KEYTRUDA®) and ® Rituximab (RITUXAN ) to evaluate safety and early efficacy signal in solid tumors and lymphoma China development goal: ▪ AML/MDS. Developing goal for registration in China for the indications TJC4 – A Differentiated CD47 Antibody in Clinical Development COMPANY OVERVIEW 11 I-MAB INVESTOR PRESENTATIONTJC4: Parallel Clinical Development in US and China US development goals: ▪ Evaluation of the safety differentiation in solid tumor/lymphoma to complete by Q3 ▪ Combination therapy with PD-1 inhibitor pembrolizumab (KEYTRUDA®) and ® Rituximab (RITUXAN ) to evaluate safety and early efficacy signal in solid tumors and lymphoma China development goal: ▪ AML/MDS. Developing goal for registration in China for the indications TJC4 – A Differentiated CD47 Antibody in Clinical Development COMPANY OVERVIEW 11 I-MAB INVESTOR PRESENTATION
TJD5: A Potential Highly Differentiated CD73 Antibody Highlights Summary of Pre-clinical Results TJD5 Pre-clinical Data Potentiation of Antitumor Activities Differentiated Property without Novel Mechanism Differentiated CD73 the Hook Effect in combination with PD-L1 Antibody Targeting Tumor Antibody Drug Candidate Microenvironment Clinical Development Plan Targeting multiple solid tumor types, with parallel development in the U.S. and China TJD5’s inhibition of CD73 by intra-dimerization Advantages Phase 1/2 clinical trial in patients with Phase 1 clinical trial in patients with advanced solid tumors including lung cancer, advanced solid tumors in partnership with Obtained IND approval from the NMPA in TRACON Pharmaceuticals September 2019 To evaluate safety & tolerability To evaluate safety & tolerability To explore PK/PD and potential A substrate non- To explore PK/PD and potential No “hook effect” through intra- efficacy of the combination therapy competitive pathway efficacy of the combination therapy dimerization mechanism with atezolizumab with Toripalimab COMPANY OVERVIEW 12 I-MAB INVESTOR PRESENTATIONTJD5: A Potential Highly Differentiated CD73 Antibody Highlights Summary of Pre-clinical Results TJD5 Pre-clinical Data Potentiation of Antitumor Activities Differentiated Property without Novel Mechanism Differentiated CD73 the Hook Effect in combination with PD-L1 Antibody Targeting Tumor Antibody Drug Candidate Microenvironment Clinical Development Plan Targeting multiple solid tumor types, with parallel development in the U.S. and China TJD5’s inhibition of CD73 by intra-dimerization Advantages Phase 1/2 clinical trial in patients with Phase 1 clinical trial in patients with advanced solid tumors including lung cancer, advanced solid tumors in partnership with Obtained IND approval from the NMPA in TRACON Pharmaceuticals September 2019 To evaluate safety & tolerability To evaluate safety & tolerability To explore PK/PD and potential A substrate non- To explore PK/PD and potential No “hook effect” through intra- efficacy of the combination therapy competitive pathway efficacy of the combination therapy dimerization mechanism with atezolizumab with Toripalimab COMPANY OVERVIEW 12 I-MAB INVESTOR PRESENTATION
TJ202: Potential Best-in-Class CD38 Antibody for Multiple Myeloma and Autoimmune Diseases Target Indication Highlights Multiple Myeloma (MM) Systemic Lupus Erythematosus (SLE) TJ202 Potentials in Differentiated First BLA • Approximately 20,500 new cases of MM • Estimated prevalence of 1.04 million in Autoimmune CD38 mAb Expected in 2021 in 2018 in Greater China 2018 in Greater China Diseases • China MM biologics market size is • China SLE biologics market size is estimated at US$ 0.8 billion in 2030 estimated at US$ 1.8 billion in 2030 • Recently marketed daratumumab in China • Belimumab is currently the world’s only has a long infusion time of administration biologic approved to treat SLE (up to 6 hours) and a high infusion • Unmet medical need for an efficacious reaction rate (IRR) and safe treatment alternative Advantages Expected Efficacy in Convenience and Safety Autoimmune Diseases TJ202 binds to CD38 overexpressed tumor cells, pathogenic CD38-positive B cells and plasma cells, killing its mediator by Shorter infusion time (0.5 Lower infusion reaction Targeting pathogenic inducing antibody-dependent cytotoxicity (ADCC) and antibody- – 2 Hours) rate (7%) CD38-positive B cells and dependent phagocytosis (ADCP) plasma cells COMPANY OVERVIEW 13 I-MAB INVESTOR PRESENTATIONTJ202: Potential Best-in-Class CD38 Antibody for Multiple Myeloma and Autoimmune Diseases Target Indication Highlights Multiple Myeloma (MM) Systemic Lupus Erythematosus (SLE) TJ202 Potentials in Differentiated First BLA • Approximately 20,500 new cases of MM • Estimated prevalence of 1.04 million in Autoimmune CD38 mAb Expected in 2021 in 2018 in Greater China 2018 in Greater China Diseases • China MM biologics market size is • China SLE biologics market size is estimated at US$ 0.8 billion in 2030 estimated at US$ 1.8 billion in 2030 • Recently marketed daratumumab in China • Belimumab is currently the world’s only has a long infusion time of administration biologic approved to treat SLE (up to 6 hours) and a high infusion • Unmet medical need for an efficacious reaction rate (IRR) and safe treatment alternative Advantages Expected Efficacy in Convenience and Safety Autoimmune Diseases TJ202 binds to CD38 overexpressed tumor cells, pathogenic CD38-positive B cells and plasma cells, killing its mediator by Shorter infusion time (0.5 Lower infusion reaction Targeting pathogenic inducing antibody-dependent cytotoxicity (ADCC) and antibody- – 2 Hours) rate (7%) CD38-positive B cells and dependent phagocytosis (ADCP) plasma cells COMPANY OVERVIEW 13 I-MAB INVESTOR PRESENTATION
Eftansomatropin TJ101: Potential Best-in-Class Long-Acting Growth Hormone for Growth Hormone Deficiency Target Indication Highlights TJ101 Pediatric Growth Hormone Deficiency (PGHD) • PGHD affected approximately 3.4 million patients in 2018 in Greater China Convenient Weekly or Bi-weekly Dosing with Safety Advantages • Huge unmet medical need as only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018 • China PGHD therapeutics market size is US$ 0.6 billion in 2018, and is estimated to increase to US$ 3.2 billion in 2030, a CAGR of 15.7% Long-Acting Short-Acting (Weekly/Bi-weekly Injection) (Daily Injection) TJ101 is engineered using Genexine’s • Jintrolong is currently the only approved proprietary hyFc technology • Short-acting rhGH is the most long-acting pegylated rhGH in China commonly used treatment in China• Potential safety concerns related to long- • Not convenient with poor patient term use of pegylated drugs compliance • TJ101 is the only Fc-based long-acting rhGH ready for a Phase 3 clinical trial in China Clinical Development Plan Currently in preparation for a Phase 3, randomized, active controlled, and multi- center study to demonstrate non-inferiority of weekly TJ101 compared to The clinical results from a Phase 2 trial in PGHD Jintropin, a daily rhGH marketed in China conducted in Europe indicated weekly or bi- weekly treatment with TJ101 produced similar efficacy compared to daily Genotropin administration IND submission expected in 2020 COMPANY OVERVIEW 14 I-MAB INVESTOR PRESENTATIONEftansomatropin TJ101: Potential Best-in-Class Long-Acting Growth Hormone for Growth Hormone Deficiency Target Indication Highlights TJ101 Pediatric Growth Hormone Deficiency (PGHD) • PGHD affected approximately 3.4 million patients in 2018 in Greater China Convenient Weekly or Bi-weekly Dosing with Safety Advantages • Huge unmet medical need as only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018 • China PGHD therapeutics market size is US$ 0.6 billion in 2018, and is estimated to increase to US$ 3.2 billion in 2030, a CAGR of 15.7% Long-Acting Short-Acting (Weekly/Bi-weekly Injection) (Daily Injection) TJ101 is engineered using Genexine’s • Jintrolong is currently the only approved proprietary hyFc technology • Short-acting rhGH is the most long-acting pegylated rhGH in China commonly used treatment in China• Potential safety concerns related to long- • Not convenient with poor patient term use of pegylated drugs compliance • TJ101 is the only Fc-based long-acting rhGH ready for a Phase 3 clinical trial in China Clinical Development Plan Currently in preparation for a Phase 3, randomized, active controlled, and multi- center study to demonstrate non-inferiority of weekly TJ101 compared to The clinical results from a Phase 2 trial in PGHD Jintropin, a daily rhGH marketed in China conducted in Europe indicated weekly or bi- weekly treatment with TJ101 produced similar efficacy compared to daily Genotropin administration IND submission expected in 2020 COMPANY OVERVIEW 14 I-MAB INVESTOR PRESENTATION
TJM2: Treatment for cytokine storm in severe COVID-19 infected patients Scientific rationale GM-CSF blockade reduced cytokines that were elevated in COVID-19 patients Cytokines downregulated by GM-CSF Cytokines upregulated in antibody treatment COVID-19 pts YG Zhou bioRxiv. https://doi.org/10.1101/2020.02.12.94557 Blood. 2019;133(7):697-709 Lancet. 2020 Jan 24. pii: S0140- 6736(20)30183-5 GM-CSF and IL-6 are two key factors instigating cytokine storm in COVID-19. Antibodies neutralizing ▪ Cytokines in red are elevated in severe COVID-19 GM-CSF or IL-6/IL-6R may be used to prevent or treat cases requiring ICU. cytokine storm associated with COVID-19. Advantages Clinical Development Plan Targeting severe COVID-19 patients in the U.S. ▪ Specifically neutralizes GM-CSF which Primary endpoints: is key factor to induce cytokine storm Part 1 Part 2 I/E criteria:• Proportion of in COVID-19 Pilot safety run-in randomized trial • RT-PCR confirmed novel deterioration in clinical ▪ Regulates the inflammatory cytokine Coronavirus infection status from baseline TJM2 Dose 1 TJM2 Dose 1 • Imaging confirmed (D14) network via the upstream intervention infection in both lungs ▪ Targets myeloid lineage cells with no R TJM2 Dose 2 TJM2 Dose 2 • Severe or critical novel Secondary endpoints: influence on lymphocytes to avoid the Coronavirus pneumonia• SOFA score Placebo Placebo • PaO2/FiO2 entire immune suppression Stratifications: • Changes in serum ▪ Supported by preclinical research and • Ventilation: yes/no cytokines safety profile of the phase 1 study • Older than 60y: yes/no• All-cause mortality • And etc. COMPANY OVERVIEW 15 I-MAB INVESTOR PRESENTATIONTJM2: Treatment for cytokine storm in severe COVID-19 infected patients Scientific rationale GM-CSF blockade reduced cytokines that were elevated in COVID-19 patients Cytokines downregulated by GM-CSF Cytokines upregulated in antibody treatment COVID-19 pts YG Zhou bioRxiv. https://doi.org/10.1101/2020.02.12.94557 Blood. 2019;133(7):697-709 Lancet. 2020 Jan 24. pii: S0140- 6736(20)30183-5 GM-CSF and IL-6 are two key factors instigating cytokine storm in COVID-19. Antibodies neutralizing ▪ Cytokines in red are elevated in severe COVID-19 GM-CSF or IL-6/IL-6R may be used to prevent or treat cases requiring ICU. cytokine storm associated with COVID-19. Advantages Clinical Development Plan Targeting severe COVID-19 patients in the U.S. ▪ Specifically neutralizes GM-CSF which Primary endpoints: is key factor to induce cytokine storm Part 1 Part 2 I/E criteria:• Proportion of in COVID-19 Pilot safety run-in randomized trial • RT-PCR confirmed novel deterioration in clinical ▪ Regulates the inflammatory cytokine Coronavirus infection status from baseline TJM2 Dose 1 TJM2 Dose 1 • Imaging confirmed (D14) network via the upstream intervention infection in both lungs ▪ Targets myeloid lineage cells with no R TJM2 Dose 2 TJM2 Dose 2 • Severe or critical novel Secondary endpoints: influence on lymphocytes to avoid the Coronavirus pneumonia• SOFA score Placebo Placebo • PaO2/FiO2 entire immune suppression Stratifications: • Changes in serum ▪ Supported by preclinical research and • Ventilation: yes/no cytokines safety profile of the phase 1 study • Older than 60y: yes/no• All-cause mortality • And etc. COMPANY OVERVIEW 15 I-MAB INVESTOR PRESENTATION
Expected Major Catalysts in 2020 Category 2020 TJC4 US TJC4 China trial TJ202 China SLE safety data readout trial start start in AML/MDS TJ101 China Ph 3 TJD5 US TJD5 China trial safety data readout start in solid tumor IND submission TJM2 US and Korea TJM2 China Ph 1b TJ301 China Ph 2 IND for CRS start in RA topline data TJ210 US IND and TJ107 China Ph 1 trial start Ph 2 trial start Clinical Milestone TJX7 US IND and Ph 1 trial start Expansion of US Manufacture facility in China R&D center Potential global or Corporate Milestone China partnerships COMPANY OVERVIEW 16 I-MAB INVESTOR PRESENTATIONExpected Major Catalysts in 2020 Category 2020 TJC4 US TJC4 China trial TJ202 China SLE safety data readout trial start start in AML/MDS TJ101 China Ph 3 TJD5 US TJD5 China trial safety data readout start in solid tumor IND submission TJM2 US and Korea TJM2 China Ph 1b TJ301 China Ph 2 IND for CRS start in RA topline data TJ210 US IND and TJ107 China Ph 1 trial start Ph 2 trial start Clinical Milestone TJX7 US IND and Ph 1 trial start Expansion of US Manufacture facility in China R&D center Potential global or Corporate Milestone China partnerships COMPANY OVERVIEW 16 I-MAB INVESTOR PRESENTATION
Senior Management with a Proven Track Record of Success Zheru Zhang, Ph.D. Jielun Zhu, MBA, CFA President CFO • 20+ years of experience in CMC and quality management in • 10+ years in investment banking, 4 years experience in pharma industry in US, Korea and China healthcare consulting • Previously served management roles at BMS, J&J and Celltrion • Served as MD and Asia Head of Healthcare Investment • Led or participated in 20 biologics IND and six global BLA Banking for Jefferies, and a core healthcare team member submissions at DB and UBS AG • Ph.D., University of Alberta• M.B.A., Harvard Business School • M.S., Suzhou University • B.A., Wesleyan University Neil K. Warma, MBA Dr. Jingwu Zang, M.D., Ph.D. Joan Shen., M.D., Ph.D. US General Manager Founder, Honorary Chairman and Director CEO and Director • Ex-President and Ex-CEO of Opexa Therapeutics • M.D., Shanghai Jiaotong University • US licensed physician with 20+ years of clinical (NASDAQ:OPXA), Ex-President and Ex-CEO of development experience and China• Ph.D., University of Brussels Viron Therapeutics, Founder and Ex-President • Ex-China Clinical Head at Pfizer, Ex-CMO at • Post-doc, Harvard Medical School of MedExact Jiangsu Hengrui, Ex-China Development Head • Clinical residency, Baylor College of Medicine, US- • Ex-Head of International Pharma Policy & at J&J licensed physician Advocacy at Novartis • Ph.D., Postdoc, Indiana University School of Industry Experiences • Board of Director of BioHouston Medicine • 12 years of pharma R&D executives • B.Sc., University of Toronto • M.S., West China University of Medical • Ex-CSO and President of Simcere Pharmaceuticals • M.B.A., Schulich School of Management at York Sciences • Corporate SVP, Head of GSK China R&D Center University • M.D., Southeast University Medical College Academic Achievements • Professor at Baylor College of Medicine • Professor & founding director in Chinese Academy of Science • Published over 160 papers in scientific journals WHO WE ARE 17 I-MAB INVESTOR PRESENTATIONSenior Management with a Proven Track Record of Success Zheru Zhang, Ph.D. Jielun Zhu, MBA, CFA President CFO • 20+ years of experience in CMC and quality management in • 10+ years in investment banking, 4 years experience in pharma industry in US, Korea and China healthcare consulting • Previously served management roles at BMS, J&J and Celltrion • Served as MD and Asia Head of Healthcare Investment • Led or participated in 20 biologics IND and six global BLA Banking for Jefferies, and a core healthcare team member submissions at DB and UBS AG • Ph.D., University of Alberta• M.B.A., Harvard Business School • M.S., Suzhou University • B.A., Wesleyan University Neil K. Warma, MBA Dr. Jingwu Zang, M.D., Ph.D. Joan Shen., M.D., Ph.D. US General Manager Founder, Honorary Chairman and Director CEO and Director • Ex-President and Ex-CEO of Opexa Therapeutics • M.D., Shanghai Jiaotong University • US licensed physician with 20+ years of clinical (NASDAQ:OPXA), Ex-President and Ex-CEO of development experience and China• Ph.D., University of Brussels Viron Therapeutics, Founder and Ex-President • Ex-China Clinical Head at Pfizer, Ex-CMO at • Post-doc, Harvard Medical School of MedExact Jiangsu Hengrui, Ex-China Development Head • Clinical residency, Baylor College of Medicine, US- • Ex-Head of International Pharma Policy & at J&J licensed physician Advocacy at Novartis • Ph.D., Postdoc, Indiana University School of Industry Experiences • Board of Director of BioHouston Medicine • 12 years of pharma R&D executives • B.Sc., University of Toronto • M.S., West China University of Medical • Ex-CSO and President of Simcere Pharmaceuticals • M.B.A., Schulich School of Management at York Sciences • Corporate SVP, Head of GSK China R&D Center University • M.D., Southeast University Medical College Academic Achievements • Professor at Baylor College of Medicine • Professor & founding director in Chinese Academy of Science • Published over 160 papers in scientific journals WHO WE ARE 17 I-MAB INVESTOR PRESENTATION
Distinguished Scientific Advisory Board Patricia LoRusso, D.O., M.A., Ph.D. Academic Achievements • Associate Director of Innovative Medicine and Director of Early Therapeutics Disease-Aligned Team at Yale Cancer Center Industry Experience • Member of the NCI Board of Scientific Council R&D Highlights • Dr. LoRusso heads the early clinical trials program at Yale Cancer Center and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years Eric K. Rowinsky, M.D. Academic Achievements • Adjunct Professor of Medicine at New York University School of Medicine Industry Experience • Advisor to C-Bridge Capital • U.S. Chief Medical Officer for Everest Medicines, Inc. R&D Highlights • At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies Howard L. Weiner, M.D. Academic Achievements • Robert L. Kroc Professor of Neurology at the Harvard Medical School Industry Experience • Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston R&D Highlights • Dr. Weiner pioneered immunotherapy in Multiple Sclerosis (MS) and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumors Yi-Long Wu, M.D. Academic Achievements • Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award) Industry Experience • Tenured Professor of Guangdong General Hospital (GGH) R&D Highlights • Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line Timothy A Yap, M.D, Ph.D. Academic Achievements • Associate Professor of Department for Investigational Cancer Therapeutics (Phase 1 Program) and the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center Industry Experience • Medical Director of the Institute for Applied Cancer Science • Associate Director of Translational Research in the Institute for Personalized Cancer Therapy R&D Highlights • Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, their acceleration through clinical studies using novel predictive and pharmacodynamics biomarkers Roy S. Herbst, M.D, Ph.D. Academic Achievements • Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology and the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital Industry Experience • Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven R&D Highlights • Dr. Herbst is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies WHO WE ARE 18 I-MAB INVESTOR PRESENTATIONDistinguished Scientific Advisory Board Patricia LoRusso, D.O., M.A., Ph.D. Academic Achievements • Associate Director of Innovative Medicine and Director of Early Therapeutics Disease-Aligned Team at Yale Cancer Center Industry Experience • Member of the NCI Board of Scientific Council R&D Highlights • Dr. LoRusso heads the early clinical trials program at Yale Cancer Center and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years Eric K. Rowinsky, M.D. Academic Achievements • Adjunct Professor of Medicine at New York University School of Medicine Industry Experience • Advisor to C-Bridge Capital • U.S. Chief Medical Officer for Everest Medicines, Inc. R&D Highlights • At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies Howard L. Weiner, M.D. Academic Achievements • Robert L. Kroc Professor of Neurology at the Harvard Medical School Industry Experience • Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston R&D Highlights • Dr. Weiner pioneered immunotherapy in Multiple Sclerosis (MS) and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumors Yi-Long Wu, M.D. Academic Achievements • Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award) Industry Experience • Tenured Professor of Guangdong General Hospital (GGH) R&D Highlights • Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line Timothy A Yap, M.D, Ph.D. Academic Achievements • Associate Professor of Department for Investigational Cancer Therapeutics (Phase 1 Program) and the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center Industry Experience • Medical Director of the Institute for Applied Cancer Science • Associate Director of Translational Research in the Institute for Personalized Cancer Therapy R&D Highlights • Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, their acceleration through clinical studies using novel predictive and pharmacodynamics biomarkers Roy S. Herbst, M.D, Ph.D. Academic Achievements • Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology and the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital Industry Experience • Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven R&D Highlights • Dr. Herbst is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies WHO WE ARE 18 I-MAB INVESTOR PRESENTATION
Dual Expertise in U.S. and China with Strategic Global Footprint of Partners (1) (1) (1) (1) (1)(2) Germany Hebei Beijing Switzerland Maryland (1) Shanghai (1) (1) (1) California New Jersey South Korea (1)(3) Indonesia Notes 1. Headquarters of companies that partner with I-Mab. 2. In April 2017, our subsidiary I-Mab Shanghai entered into a technology transfer agreement (the “HDYM License”) with Ningbo Hou De Yi Min Information Technology Co., Ltd. (“HDYM”) and Hangzhou HealSun Biopharm Co., Ltd. (“HealSun”), which is a portfolio company of Lepu Biotech. 3. In March 2020, our subsidiary I-Mab Biopharma US Limited entered into a strategic alliance agreement with Kalbe Genexine Biologics, a joint venture between Kalbe Farma Tbk and Genexine, Inc. GLOBAL PARTNERSHIP 19 I-MAB INVESTOR PRESENTATIONDual Expertise in U.S. and China with Strategic Global Footprint of Partners (1) (1) (1) (1) (1)(2) Germany Hebei Beijing Switzerland Maryland (1) Shanghai (1) (1) (1) California New Jersey South Korea (1)(3) Indonesia Notes 1. Headquarters of companies that partner with I-Mab. 2. In April 2017, our subsidiary I-Mab Shanghai entered into a technology transfer agreement (the “HDYM License”) with Ningbo Hou De Yi Min Information Technology Co., Ltd. (“HDYM”) and Hangzhou HealSun Biopharm Co., Ltd. (“HealSun”), which is a portfolio company of Lepu Biotech. 3. In March 2020, our subsidiary I-Mab Biopharma US Limited entered into a strategic alliance agreement with Kalbe Genexine Biologics, a joint venture between Kalbe Farma Tbk and Genexine, Inc. GLOBAL PARTNERSHIP 19 I-MAB INVESTOR PRESENTATION
Strategic Partnerships with Leading Global Companies Multiple Collaborations Established with Quality Partners Product Partner Partner Market Cap Ticker Commercial Rights Date In-license Olamkicept (IL-6 blocker) Private Private Greater China, S. Korea 2016.11 TJ202 (CD38) FRA: MOR, Greater China 2017.11/ US$ 3.4Bn TJ210 (C5aR) NASDAQ: MOR Greater China, S. Korea 2018.11 TJ101 (Long-acting hGH) / China 2015.10/ US$ 1.1Bn KOSDAQ: 095700 Efineptakin TJ107 Greater China 2017.12 Enoblituzumab (B7-H3 antibody) US$ 549.6Mn NASDAQ: MGNX Greater China 2019.07 Partnership WuXiBody Platform 2018.09/ Strategic Manufacturing Partner US$ 12.9Bn SEHK: 2269 Worldwide 2019.04/ Investor 2019.07 Strategic Commercial Partner US$ 2.9Bn IDX:KLBF South East Asia, MENA 2020.03 Co-development Tecentriq for combo with TJD5 US$ 247.0Bn SWX: ROG Global (excl China) 2019.03 KEYTRUDA® (pembrolizumab) for US$ 216.8Bn NYSE:MRK Worldwide 2019.09 combo with TJC4 Toripalimab (anti-PD-1 mAb) for SEHK: 1877, US$ 2.8Bn China 2019.09 combo with TJD5 NEEQ: 833330 TJD5 (CD73 antibody) US$ 9.0Mn NASDAQ: TCON North America 2018.11 Out-license PD-L1 antibody US$ 6.9Bn SZSE: 300003 Worldwide 2017.04 Bispecific antibody US$ 734.9Mn KOSDAQ: 298380 Ex- Greater China 2018.07 TJ103 US$ 13.3Bn SEHK: 1093 Greater China 2018.12 long-acting GLP-1 GLOBAL PARTNERSHIP 20 I-MAB INVESTOR PRESENTATIONStrategic Partnerships with Leading Global Companies Multiple Collaborations Established with Quality Partners Product Partner Partner Market Cap Ticker Commercial Rights Date In-license Olamkicept (IL-6 blocker) Private Private Greater China, S. Korea 2016.11 TJ202 (CD38) FRA: MOR, Greater China 2017.11/ US$ 3.4Bn TJ210 (C5aR) NASDAQ: MOR Greater China, S. Korea 2018.11 TJ101 (Long-acting hGH) / China 2015.10/ US$ 1.1Bn KOSDAQ: 095700 Efineptakin TJ107 Greater China 2017.12 Enoblituzumab (B7-H3 antibody) US$ 549.6Mn NASDAQ: MGNX Greater China 2019.07 Partnership WuXiBody Platform 2018.09/ Strategic Manufacturing Partner US$ 12.9Bn SEHK: 2269 Worldwide 2019.04/ Investor 2019.07 Strategic Commercial Partner US$ 2.9Bn IDX:KLBF South East Asia, MENA 2020.03 Co-development Tecentriq for combo with TJD5 US$ 247.0Bn SWX: ROG Global (excl China) 2019.03 KEYTRUDA® (pembrolizumab) for US$ 216.8Bn NYSE:MRK Worldwide 2019.09 combo with TJC4 Toripalimab (anti-PD-1 mAb) for SEHK: 1877, US$ 2.8Bn China 2019.09 combo with TJD5 NEEQ: 833330 TJD5 (CD73 antibody) US$ 9.0Mn NASDAQ: TCON North America 2018.11 Out-license PD-L1 antibody US$ 6.9Bn SZSE: 300003 Worldwide 2017.04 Bispecific antibody US$ 734.9Mn KOSDAQ: 298380 Ex- Greater China 2018.07 TJ103 US$ 13.3Bn SEHK: 1093 Greater China 2018.12 long-acting GLP-1 GLOBAL PARTNERSHIP 20 I-MAB INVESTOR PRESENTATION
Strong Shareholder Base with Prominent Investors Raised over US$500 Million in 3 Years with Leading Chinese and Global Healthcare and Biotech Investors 2020Q1 Inception - 2016 2016Q3 2017Q3 2018Q3 2019Q3 US$ 114.5 Million US$ 27 Million US$ 200 Million U.S. IPO Series C-1 US$ 120 Million Series C US$ 58 Million US$ 2.3Million Series B Series A Angel NASDAQ: IMAB OUR INVESTORS 21 I-MAB INVESTOR PRESENTATIONStrong Shareholder Base with Prominent Investors Raised over US$500 Million in 3 Years with Leading Chinese and Global Healthcare and Biotech Investors 2020Q1 Inception - 2016 2016Q3 2017Q3 2018Q3 2019Q3 US$ 114.5 Million US$ 27 Million US$ 200 Million U.S. IPO Series C-1 US$ 120 Million Series C US$ 58 Million US$ 2.3Million Series B Series A Angel NASDAQ: IMAB OUR INVESTORS 21 I-MAB INVESTOR PRESENTATION
Raised Over US $500 Million with Leading Global Healthcare and Biotech Investors (1)(3) Shareholder Breakdown Fundraising History Others 18% CBC Group 31% Round Amount ($USD) Seed $2.3M (2) Other IPO Series A $58M shareholders 11% Series B $120M Series C $200M Founders 3% Series C-1 $27M Wuxi Biologics Tigermed IPO $115M 1% Tasly 2% TOTAL $522.3M 11% Lake Bleu 2% Hillhouse 3% GIC Hony Capital Genexine 4% 7% 7% Note: 1. Based on common shares outstanding 2. Other IPO shareholders exclude: GIC, Genexine, Lake Bleu, C-Bridges (2) 3. ESOP on fully diluted basis is 13.4% of shares outstanding OUR INVESTORS 22 I-MAB INVESTOR PRESENTATIONRaised Over US $500 Million with Leading Global Healthcare and Biotech Investors (1)(3) Shareholder Breakdown Fundraising History Others 18% CBC Group 31% Round Amount ($USD) Seed $2.3M (2) Other IPO Series A $58M shareholders 11% Series B $120M Series C $200M Founders 3% Series C-1 $27M Wuxi Biologics Tigermed IPO $115M 1% Tasly 2% TOTAL $522.3M 11% Lake Bleu 2% Hillhouse 3% GIC Hony Capital Genexine 4% 7% 7% Note: 1. Based on common shares outstanding 2. Other IPO shareholders exclude: GIC, Genexine, Lake Bleu, C-Bridges (2) 3. ESOP on fully diluted basis is 13.4% of shares outstanding OUR INVESTORS 22 I-MAB INVESTOR PRESENTATION
Well Capitalized to Pursue Ongoing R&D Activities (1) Historical Revenue Total Cash Position 53.8 RMB MM 30.0 11.6 2017 Revenue 2018 Revenue 2019 Revene RMB MM US$ 115MM US$ 245MM 1,800 2019 R&D Expenses US$ 176MM US$ 115MM 1,200 2019 R&D expenses total RMB$840.4MM (US$120.7MM) which primarily consists of: 1,681.0 1,225.3 600 US$ 60MM ▪ CRO service fees ▪ In-licensed patent right fees, including US$15mil 412.7 upfront payment to MacroGenics 0 ▪ Employment benefit expenses, including upfront 2017 2018 2019 Jan 2020 IPO Gross Proceeds R&D staff salary and benefits payment Total Cash Position ▪ Material cost for drug candidates Note: 1. Total cash position include: cash and cash equivalent, restricted cash, and short-term investments. Restricted cash represents cash that cannot be withdrawn without the permission of third parties, and deposits held in a separate reserve account as security deposits under bank borrowing agreements FINANCIAL POSITION 23 I-MAB INVESTOR PRESENTATIONWell Capitalized to Pursue Ongoing R&D Activities (1) Historical Revenue Total Cash Position 53.8 RMB MM 30.0 11.6 2017 Revenue 2018 Revenue 2019 Revene RMB MM US$ 115MM US$ 245MM 1,800 2019 R&D Expenses US$ 176MM US$ 115MM 1,200 2019 R&D expenses total RMB$840.4MM (US$120.7MM) which primarily consists of: 1,681.0 1,225.3 600 US$ 60MM ▪ CRO service fees ▪ In-licensed patent right fees, including US$15mil 412.7 upfront payment to MacroGenics 0 ▪ Employment benefit expenses, including upfront 2017 2018 2019 Jan 2020 IPO Gross Proceeds R&D staff salary and benefits payment Total Cash Position ▪ Material cost for drug candidates Note: 1. Total cash position include: cash and cash equivalent, restricted cash, and short-term investments. Restricted cash represents cash that cannot be withdrawn without the permission of third parties, and deposits held in a separate reserve account as security deposits under bank borrowing agreements FINANCIAL POSITION 23 I-MAB INVESTOR PRESENTATION
Financial Summary Selected Financials Full Year Ended (All amounts in RMB thousands, except for per share data) December 31, 2018 December 31, 2019 Cash, Cash Equivalents, Restricted Cash and Short-Term Investments 1,680,931 1,225,283 Total Revenues 53,781 30,000 (Licensing and Collaboration Revenue) Total Expenses (492,419) (1,494,968) Research & Development Expenses (426,028) (840,415) Administrative Expenses (66,391) (654,553) Net Loss (402,833) (1,451,950) Net Loss Attributable to Ordinary Shareholders (402,833) (1,485,001) Net Loss Per Share Attributable to Ordinary Shareholders (61.7) (201.2) (Basic and Diluted) Non-GAAP Adjusted Net Loss (399,313) (936,747) Non-GAAP Adjusted Net Loss Attributable to Ordinary Shareholders (399,313) (969,798) Non-GAAP Adjusted Net Loss Per Share Attributable to Ordinary (61.2) (131.4) Shareholders (Basic and Diluted) FINANCIALS 24 I-MAB INVESTOR PRESENTATION FINANCIAL POSITION 24Financial Summary Selected Financials Full Year Ended (All amounts in RMB thousands, except for per share data) December 31, 2018 December 31, 2019 Cash, Cash Equivalents, Restricted Cash and Short-Term Investments 1,680,931 1,225,283 Total Revenues 53,781 30,000 (Licensing and Collaboration Revenue) Total Expenses (492,419) (1,494,968) Research & Development Expenses (426,028) (840,415) Administrative Expenses (66,391) (654,553) Net Loss (402,833) (1,451,950) Net Loss Attributable to Ordinary Shareholders (402,833) (1,485,001) Net Loss Per Share Attributable to Ordinary Shareholders (61.7) (201.2) (Basic and Diluted) Non-GAAP Adjusted Net Loss (399,313) (936,747) Non-GAAP Adjusted Net Loss Attributable to Ordinary Shareholders (399,313) (969,798) Non-GAAP Adjusted Net Loss Per Share Attributable to Ordinary (61.2) (131.4) Shareholders (Basic and Diluted) FINANCIALS 24 I-MAB INVESTOR PRESENTATION FINANCIAL POSITION 24